The evaluation of the effect of brewed chicory leaf consumption in patients with non-alcoholic fatty liver disease

The evaluation of the effect of brewed chicory leaf consumption on liver steatosis, enzymes, metabolic syndrome components, oxidative stress markers, C-reactive protein in patients with non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190819044565N2

Enrollment

Registered

2019-12-24

Start date

2019-10-23

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease. Other diseases of liver

Interventions

Intervention 1: Intervention group: Apart from routine treatment by the gastroenterologist, they will receive 15 grams of chicory leaf daily for 12 weeks and And they will use dietary guidelines for I

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Grade 2 and 3 non-alcoholic fatty liver disease through observation of steatosis in ultrasound Older than 18 years Interested in attending in study that filled out an informed consent form

Exclusion criteria

Exclusion criteria: Mental, emotional, cognitive and mental disorders Grade 1 non-alcoholic fatty liver disease alcohol consumption Hepatitis B, Hepatitis C, Autoimmune Hepatitis, Liver Cancer, Cholestatic Liver Disease Rheumatoid arthritis and other acute inflammatory diseases Taking non-steroidal anti-inflammatory drugs, cholesterol-lowering drugs to control blood pressure such as statins, phenytoin, karmabazepine and barbiturates such as phenobarbital Alpha-1 antitrypsin deficiency Pancreatitis Heart failure Bone diseases Coeliac disease Supplement of Vitamin, Antioxidant, Fiber and Omega 3 Do not regularly use of brewed chicory leaf during the study Use of anticoagulants Hepatotoxic drugs Hereditary hemochromatosis Wilson's disease Pregnant women Lactating women Use of contraceptives drugs liver transplant kidney diseases Changes in the level of physical activity during the study Diabetes Mellitus Hypothyroidism

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: ultrasound.;Alanine transaminase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Aspartate transaminase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Gamma-glutamyl transferase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Alkaline phosphatase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;High-density lipoprotein. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Low-density lipoprotein. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Triglyceride. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Cholesterol. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;FBS. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Total antioxidant capacity. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Superoxide dismutase. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Hs-CRP. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.	—

Measure

Time frame

Hepatic steatosis. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: ultrasound.;Alanine transaminase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Aspartate transaminase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Gamma-glutamyl transferase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Alkaline phosphatase. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;High-density lipoprotein. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Low-density lipoprotein. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Triglyceride. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Cholesterol. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;FBS. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Total antioxidant capacity. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Superoxide dismutase. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Hs-CRP. Timepoint: Beginning and end of study (after 12 weeks). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.

—

Secondary

Measure	Time frame
Insulin. Timepoint: Beginning and End of Study (Week 12). Method of measurement: ELISA method, BT1500 machine.;HOMA-IR. Timepoint: Beginning and End of Study (Week 12). Method of measurement: Formula.;QUICKI. Timepoint: Beginning and End of Study (Week 12). Method of measurement: Formula.;Albumin. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Creatinine. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Bilirubin total. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;CBC. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Using the cell counter.;Calcium. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Phosphorus. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Sodium. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: blood sample.;Potassium. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: blood sample.;Mean systolic and diastolic blood pressure. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: blood pressure monitor.	—

Measure

Time frame

Insulin. Timepoint: Beginning and End of Study (Week 12). Method of measurement: ELISA method, BT1500 machine.;HOMA-IR. Timepoint: Beginning and End of Study (Week 12). Method of measurement: Formula.;QUICKI. Timepoint: Beginning and End of Study (Week 12). Method of measurement: Formula.;Albumin. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Creatinine. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Bilirubin total. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;CBC. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Using the cell counter.;Calcium. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Phosphorus. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: Enzymatic method with autoanalysis, BT1500 machine.;Sodium. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: blood sample.;Potassium. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: blood sample.;Mean systolic and diastolic blood pressure. Timepoint: First, Sixth Week and End of Study (Week 12). Method of measurement: blood pressure monitor.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Faraji

Oroumia University of Medical Sciences

FarajiSamira2019@yahoo.com+98 41 3343 6241

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026